Clinical Trial Update: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of encorafenib plus binimetinib for BRAF V600-mutated hairy cell leukemia, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 2 | Status: RECRUITING